4.5 Review

Heart failure as a general pandemic in Asia

期刊

EUROPEAN JOURNAL OF HEART FAILURE
卷 17, 期 9, 页码 884-892

出版社

WILEY
DOI: 10.1002/ejhf.319

关键词

Heart failure; Ageing; Asia; Prevention

资金

  1. Bayer Yakuhin, Ltd (Osaka, Japan)
  2. Daiichi Sankyo Co., Ltd (Tokyo, Japan)
  3. Novartis Pharma K.K. (Tokyo, Japan)
  4. Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan)
  5. Kowa Pharmaceutical Co., Ltd (Tokyo, Japan)
  6. Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan),
  7. Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan)

向作者/读者索取更多资源

Heart failure (HF) is epidemic in healthcare worldwide, including Asia. It appears that HF will become more serious in the near future, with the epidemiological transition and ageing of the population. However, in contrast to Western countries, information on HF epidemiology is still limited in Asia, particularly in South Asia. In this review, we will briefly summarize available information regarding the current and future burden of HF in Asia, which indicates the importance of both primary prevention of underlying diseases of HF and secondary prevention, including management of ischaemic HF, HF with preserved EF, and HF in the elderly.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据